Gut Imaging for Function & Transit in Cystic Fibrosis Study 2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-03

Study Completion Date

2020-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with Cystic Fibrosis (CF) have problems digesting their food properly. More than 8 in 10 people with CF must take medication to assist their digestion. In spite of this, complications such as bowel blockage occur.

Finding out how already licenced drugs for CF work in the gut is the first step in repurposing medications. Tezacaftor/Ivacaftor with Ivacaftor is a drug combination which corrects the basic defect in CF an has shown improvements on lung function.

The purpose of this study is to evaluate, using Magnetic Resonance Imaging (MRI) and patient-reported outcomes, whether Tezacaftor/Ivacaftor with Ivacaftor has an effect on improving gastrointestinal problems in CF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior

NCT05699148

Cystic Fibrosis

UNKNOWN

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457

Cystic Fibrosis

COMPLETED PHASE3

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT02508207

Cystic Fibrosis

COMPLETED PHASE2

Gut Imaging for Function & Transit in CF - GIFT-CF 3

NCT04618185

Cystic Fibrosis

COMPLETED

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

NCT01614470

Cystic Fibrosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a small pilot study to compare the effects of active drug (Tezacaftor/Ivacaftor with Ivacaftor) on the gut in people with CF.

Participants will be randomised to take active drug or matched placebo for 28 days then switch to the alternate drug after a 28 day washout period. Before participants commence treatment, they will have blood pressure and baseline blood tests.

Participants will attend once per treatment period for MRI scanning at the Sir Peter Mansfield Imaging Centre, after an overnight fast. On this day, participants will be asked to withhold any medicines directly altering bowel habit such as laxatives. They will continue to take pancreatic enzyme replacement therapy and other medications for CF.

The Investigators will use the same MRI protocol as described in GIFT-CF (NCT03566550). Participants will have their first MRI scan fasted. After the first scan, they will eat a first standardised meal . They will then have 7 MRI scans at half hourly intervals and 3 MRI scans at hourly intervals. Participants will be given a second standardised meal after their ninth MRI scan. Each MRI scan will last approximately 15 minutes. After each MRI scan, participants will complete a validated gastrointestinal symptom questionnaire (Gastrointestinal Symptom Rating Scale). In between scans, participants will have access to an adjacent room with Wifi and television access.

During the day, participants will have their lung function, blood pressure and blood tests taken. They will also provide a sputum and stool sample.

Infection control requirements mean that only 1 participant will attend for MRI scanning per day.

\*\*\*Amendment to study due to COVID-19\*\*\* From mid-March 2020, all face to face clinical research in the UK has been suspended (apart from studies directly related to the COVID-19 pandemic). Patients in the GIFT-CF 2 trial who had not yet completed the full trial protocol were therefore unable to continue. Funding for SymkeviTM (tezacaftor/ivacaftor and ivacaftor) in the UK was announced at the end of 2019 and some of the trial participants, who have not completed GIFT-CF 2, may be prescribed SymkeviTM by their CF team. It will therefore not be possible for them to complete the placebo controlled cross-over trial, once COVID restrictions are eased. We plan to mitigate the effects of COVID-related disruption by ensuring all trial participants have had the full, protocol-defined, scan sequence both on and off SymkeviTM. When restrictions are eased, we will invite participants who have been prescribed SymkeviTM by their CF centre to attend for scanning, if they have not previously had an "on treatment" scan. We will follow the same scanning protocol. We will ensure that adherence to SymkeviTM is good and they have received at least 21 days of treatment (as specified in the trial protocol). Our primary analysis will be on the patients who completed the trial per protocol but we will present a secondary analysis on all 12 patients, comparing outcome measures on SymkeviTM with their outcome measures previously recorded at baseline (off treatment). The personnel interpreting the MRI scans will be blind to whether they were performed on or off SymkeviTM - reducing the probability of observer bias.

\*\*\*Post hoc analysis\*\*\* For participants who are invited for an open-label "on treatment" MRI scan day, the statistical analysis will involve a comparison between their pre-treatment MRI scans and the open-label scan. The researcher analysing the images will remain blinded. Statistical analysis for these participants will be a comparison between their pre-treatment scan and open-label on-treatment scan. Motility outcomes will not be analysed as the specific MR sequencing was adapted to focus on the terminal ileum in the cross-over trial, whilst in the pre-treatment scans, the motility was across the whole small bowel.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tezacaftor/Ivacaftor in combination with Ivacaftor

A film-coated tablet containing 100mg tezacaftor and 150mg ivacaftor will be taken in the morning.

A film-coated tablet containing 150mg ivacaftor will be taken in the evening.

Participants will take these tablets for 28 days.

All tablets are licensed for use in the EU.

Group Type ACTIVE_COMPARATOR

Tezacaftor/Ivacaftor + Ivacaftor

Intervention Type DRUG

As per description in arms.

Placebo

A visually matched placebo to the active drugs will be taken in the morning and in the evening for 28 days.

Group Type PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type DRUG

As per description in arms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tezacaftor/Ivacaftor + Ivacaftor

As per description in arms.

Intervention Type DRUG

Placebo oral tablet

As per description in arms

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VX-661 100mg / VX-770 150mg active tablets VX-770 150mg active tablets Matching placebo tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* capacity to consent, or to understand the requirements of the study where parental consent is needed
* confirmed diagnosis of CF, either by sweat test or genetic testing. Tezacaftor/Ivacaftor is indicated only for patients homozygous for the commonest CF mutation - p.Phe508del and so we will enrol only CF patients with this genotype

Exclusion Criteria

* currently taking CFTR modulator drug
* Contra-indication to use of Tezacaftor/Ivacaftor
* Measurement of FEV1 \<40% predicted using Global Lung Initiative criteria, according to clinical records, as participants will be required to perform a series of 10 second breathholds throughout MRI scanning
* Contra-indication to MRI scanning, such as embedded metal, pacemaker.
* Pregnancy
* Unable to stop medications directly prescribed to alter bowel habit, such as laxatives or anti-diarrhoeals, on the study day
* Previous resection of any part of the gastrointestinal tract apart from appendicectomy or cholecystectomy. Surgical relief of meconium ileus or DIOS will be permitted unless clinical records show excision of intestine \>20cm in length.
* Intestinal stoma
* Diagnosis of inflammatory bowel disease or coeliac disease confirmed by biopsy
* Gastrointestinal malignancy
* Unable to comply with dietary restrictions required for the study.

Minimum Eligible Age

12 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No